logo

Protagonist Therapeutics, Inc (PTGX)



Trade PTGX now with
  Date
  Headline
8/7/2019 7:07:26 AM Protagonist Therapeutics Q2 Net Loss $29.2 Mln Vs. Net Loss $8.7 Mln Last Year
5/29/2019 4:31:43 PM Protagonist Therapeutics Appoints Don Kalkofen As CFO
5/8/2019 7:13:07 AM Protagonist Therapeutics Q1 Net Loss $14.1 Mln Vs. Net Loss $7.7 Mln Last Year
3/12/2019 4:04:31 PM Protagonist Therapeutics Q4 Loss/share $0.57 Vs. Loss $0.15 Year Ago
1/9/2019 7:02:22 AM Protagonist Therapeutics Initiates Phase 2 Trial Of Novel Hepcidin Mimetic PTG-300 For Beta Thalassemia
1/7/2019 7:12:13 AM Protagonist Therapeutics Appoints Suneel Gupta As EVP Of Clinical Operations And Pharmacology
12/13/2018 7:04:41 AM Protagonist Therapeutics Initiates Phase 1 Trial Of Oral, Gut-Restricted, Alpha-4-Beta-7 Integrin Antagonist PN-10943
10/22/2018 8:36:53 AM Protagonist Therapeutics Presents Clinical Data From PROPEL Study Of PTG-100 In Ulcerative Colitis
10/8/2018 7:15:29 AM Protagonist Therapeutics: William Sandborn To Present Clinical Data From Phase 2 Study Of PTG-100
9/27/2018 7:06:52 AM Protagonist Therapeutics Announces Fast Track Designation Granted By U.S. FDA To Hepcidin Mimetic PTG-300
9/6/2018 7:05:24 AM Protagonist Therapeutics Receives $1.45 Mln SBIR Funding For Development Of PTG-300
  
 
>